Melanoma Clinical Trial

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Summary

This study is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy in participants with advanced melanoma refractory to checkpoint inhibitor therapy.

View Full Description

Full Description

This Phase 2 study will enroll up to approximately 200 evaluable adult participants with a histologically confirmed diagnosis of either Stage III (unresectable) or Stage IV cutaneous melanoma and who have had prior treatments with anti-programmed death (ligand) 1 [PD-(L)1].

This study will consist of 2 cohorts. In the first cohort, participants previously treated with only anti-PD-(L)1 therapy will receive botensilimab. In the second cohort, participants previously treated with anti-PD-(L)1 and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) therapies will receive botensilimab.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

To participate in the study, participants must meet all the following inclusion criteria:

Cohort A only:

Prior treatment with anti-PD-(L)1 therapy at least 6 weeks and radiologic progression confirmed by 2 scans at least 4 weeks apart, or if symptomatic due to progressive malignancy, then 1 scan showing progression is sufficient.
Prior progression must be either on treatment with anti-PD-(L)1 regimen or ≤ 12 weeks from last anti-PD-(L)1 dose in metastatic setting or ≤ 24 weeks from completion of therapy in adjuvant/ neoadjuvant setting.

Cohort B only:

Prior treatment with first-generation anti-CTLA-4 therapy (for example, ipilimumab or tremelimumab).
Prior treatment with anti-PD-(L)1.
Radiologic progression on most recent anti-neoplastic therapy confirmed by scan.

Cohorts A and B:

Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures.
Histological confirmation of Stage III (unresectable) or Stage IV cutaneous melanoma, per the American Joint Committee on Cancer 8th edition staging system.
Measurable disease on baseline imaging per RECIST 1.1 criteria.
BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period.
Life expectancy ≥ 3 months.
Eastern Cooperative Oncology Group performance status of 0 or 1.

Adequate organ function is defined as the following laboratory values within 21 days of Cycle 1 Day 1 (C1D1):

Neutrophils > 1500/microliter (μL) (stable off any growth factor within 4 weeks of first study treatment administration).
Platelets > 100 × 10^3/μL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration).
Hemoglobin > 8.0 grams/deciliter (g/dL) (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration).
Creatinine clearance ≥ 45 milliliters/minute (measured or calculated using modification of diet in renal disease).
Aspartate aminotransferase/alanine aminotransferase < 3.0 × upper limit of normal (ULN).
Total bilirubin < 1.5 × ULN, or < 3.0 × ULN for participants with Gilbert syndrome.
Albumin ≥ 3.0 g/dL.
International normalized ratio or prothrombin time ≤ 1.5 × ULN and activated partial thromboplastin time ≤ 1.5 × ULN (unless participant is receiving anticoagulant therapy).
Formalin-fixed paraffin-embedded tumor tissue sample from the most recent biopsy of a tumor lesion is required, if available. If recent tumor tissue is unavailable or inadequate, a fresh biopsy would be required, unless found to be not safe and feasible for the participant.
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study medication) and prior to study drug administration. WOCBP must agree to use highly effective contraceptive measures starting with the screening visit through 90 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.
Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial, starting with the Screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

Exclusion Criteria:

To participate in the study, participants must meet none of the following exclusion criteria:

Cohort A:

1. Received prior anti-CTLA-4 therapy.

Cohort B:

1. Received prior Fc-engineered or Fc-enhanced anti-CTLA-4 therapy (for example, BMS-96218, BMS-986288, HBM4003, XTX101, CTLA-4 targeting bispecific or other approaches such as ONC-392).

Cohorts A and B:

Ocular, uveal, or mucosal melanoma.
Any persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] ≥ 2) from prior cancer therapy, excluding endocrinopathies stable on medication, stable neuropathy, and alopecia.
Any history of CTCAE ≥ 3 immune-mediated toxicity (excluding endocrinopathies and non-necrotizing/bullous rash) from prior checkpoint inhibition.
Refractory ascites require 2 or more therapeutic paracentesis in the last 4 weeks or ≥ 4 within the last 90 days prior to study entry.
Bowel obstruction or impending bowel obstruction within the past 3 months.
Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class ≥ III), or serious uncontrolled cardiac arrhythmia requiring medication.

Active brain metastases or leptomeningeal metastases with the following exceptions:

Treated brain metastases require a) surgical resection, or b) stereotactic radiosurgery. These participants must be off steroids ≥ 10 days prior to randomization for the purpose of managing their brain metastases. Repeat brain imaging following surgical resection or stereotactic radiosurgery is not required if their last brain magnetic resonance imaging is within screening window. Whole-brain radiation is not allowed.
Untreated isolated brain metastases that are too small for treatment by surgical resection or stereotactic radiosurgery (for example, 1-2 millimeters) and/or of uncertain etiology are potentially eligible but need to be discussed with and approved by the study Medical Monitor.
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment (that is, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before the first dose of study treatment and the participant has no evidence of disease). Participants with history of prior early-stage basal/squamous cell skin cancer, low-risk prostate cancer eligible for active surveillance or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.

Treatment with 1 of the following classes of drugs within the delineated time window prior to C1D1:

Cytotoxic, targeted therapy or other investigational therapy within 3 weeks.
Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or similar therapy, within 4 weeks, or 5 half-lives, whichever is shorter.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine or booster < 7 days before C1D1. For vaccines requiring more than 1 dose, the full series should be completed prior to C1D1, when feasible. A booster shot is not required but also must be administered > 7 days from C1D1 or > 7 days from future cycle on study.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.
History of allogeneic organ transplant.
Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years before starting treatment (that is, with use of disease-modifying agents or immunosuppressive drugs).
History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the participants participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
Pregnant or breastfeeding or WOCBP who are not willing to employ effective birth control from screening to 90 days after the last dose of botensilimab (whichever is later).
Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.
Uncontrolled infection with human immunodeficiency virus (HIV). Participants on stable highly active antiretroviral therapy with undetectable viral load and normal cluster of differentiation 4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Participants who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for HBV at screening is not required.
Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Participants on or who have received antiretroviral therapy are eligible, provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for HCV at screening is not required.
Dependence on total parenteral nutrition.

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

200

Study ID:

NCT05529316

Recruitment Status:

Not yet recruiting

Sponsor:

Agenus Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 44 Locations for this study

See Locations Near You

Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale Arizona, 85258, United States More Info
Justin Moser
Principal Investigator
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton California, 92835, United States More Info
David Park
Principal Investigator
Providence Saint John's Health Center
Santa Monica California, 90404, United States More Info
Kim Margolin
Principal Investigator
Yale University School of Medicine - Yale Cancer Center
New Haven Connecticut, 06520, United States More Info
Harriet Kluger
Principal Investigator
Georgetown University Medical Center
Washington District of Columbia, 20057, United States More Info
Michael Atkins
Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Andrew Pecora
Principal Investigator
Universitair Ziekenhuis Brussel
Jette , 1090, Belgium More Info
Bart Neyns
Principal Investigator
Oncosite - Centro de Pesquisa Clinica Em Oncologia
Ijuí , 98700, Brazil More Info
Fabio Franke
Principal Investigator
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
Jaú , 17210, Brazil More Info
Patricia Medeiros Milhomem Beato
Principal Investigator
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Porto Alegre , 90110, Brazil More Info
Alan Arrieira Azambuja
Principal Investigator
INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro , 20220, Brazil More Info
Andreia de Melo
Principal Investigator
Hospital Sirio Libanes
São Paulo , 01308, Brazil More Info
Rodrigo Ramella Munhoz
Principal Investigator
Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo
São Paulo , 01323, Brazil More Info
Veridiana Pires de Camargo
Principal Investigator
Hospital A.C. Camargo Cancer Center
São Paulo , 01509, Brazil More Info
Milton Barros
Principal Investigator
CHU Amiens Picardie - Hopital Sud
Amiens , 80054, France More Info
Jean-Philippe Arnault
Principal Investigator
CHU Grenoble-Alpes - Hopital Michallon
La Tronche , 38700, France More Info
Sabiha Trabelsi-Messai
Principal Investigator
Centre Leon Berard
Lyon , 69008, France More Info
Eve-Marie Neidhardt-Berard
Principal Investigator
CHU de Nantes
Nantes Cedex 1 , 44093, France More Info
Gaelle Quereux
Principal Investigator
AP-HP Hopital Saint-Louis
Paris , 75010, France More Info
Celeste Lebbe
Principal Investigator
Centre Eugene Marquis
Rennes , 35042, France More Info
Marc Pracht
Principal Investigator
Gustave Roussy
Villejuif , 94805, France More Info
Caroline Robert
Principal Investigator
Universitaetsklinikum Essen
Essen , 45147, Germany More Info
Dirk Schadendorf
Principal Investigator
Universitaetsklinikum Hamburg-Eppendorf
Hamburg , 20246, Germany More Info
Christoffer Gebhardt
Principal Investigator
Universitaetsklinikum Heidelberg
Heidelberg , 69120, Germany More Info
Jessica Hassel
Principal Investigator
University Hospital Schleswig-Holstein
Kiel , 24105, Germany More Info
Axel Hauschild
Principal Investigator
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz , 55131, Germany More Info
Stephan Grabbe
Principal Investigator
Klinikum der Universitaet München
Munich , 80377, Germany More Info
Lucie Heinzerling
Principal Investigator
Universitaetsklinikum Tuebingen
Tuebingen , 72076, Germany More Info
Teresa Amaral
Principal Investigator
Universitaetsklinikum Würzburg
Würzburg , 97080, Germany More Info
Bastian Schilling
Principal Investigator
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
Meldola , 47014, Italy More Info
Massimo Guidoboni
Principal Investigator
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Napoli , 80131, Italy More Info
Paolo Ascierto
Principal Investigator
Azienda Ospedaliero Universitaria Senese
Siena , 53100, Italy More Info
Michele Maio
Principal Investigator
Hospital Universitario Vall d'Hebron
Barcelona , 8035, Spain More Info
Eva Muñoz Couselo
Principal Investigator
Hospital Clinic Barcelona
Barcelona , 8036, Spain More Info
Ana Arance Fernández
Principal Investigator
Onkologikoa
Donostia , 20014, Spain More Info
Karmele Mujika
Principal Investigator
Hospital General Universitario Gregorio Maranon
Madrid , 28009, Spain More Info
Ivan Márquez Rodas
Principal Investigator
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain More Info
Guillermo Antonio de Velasco Oria de Rueda
Principal Investigator
Hospital Universitario Virgen Macarena
Sevilla , 41009, Spain More Info
Luis de la Cruz
Principal Investigator
Consorcio Hospital General Universitario de Valencia
Valencia , 46014, Spain More Info
Alfonso Berrocal
Principal Investigator
CHUV - Centre hospitalier universitaire vaudois
Lausanne , 1011, Switzerland More Info
Olivier Michielin
Principal Investigator
Universitaetsspital Zuerich
Zuerich , CH-80, Switzerland More Info
Reinhard Dummer
Principal Investigator
Royal Marsden Foundation Trust
London , SW3 6, United Kingdom More Info
James Larkin
Principal Investigator
The Christie NHS Foundation Trust
Manchester , M20 4, United Kingdom More Info
Paul Lorigan
Principal Investigator
Mount Vernon Cancer Centre
Middlesex , HA6 2, United Kingdom More Info
Paul Nathan
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 2

Estimated Enrollment:

200

Study ID:

NCT05529316

Recruitment Status:

Not yet recruiting

Sponsor:


Agenus Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.